AB Science (A8D) Stock Overview

A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. More details

A8D fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Trading at 97.6% below our estimate of its fair value

Revenue is forecast to grow 72.01% per year

Earnings have grown 18.5% per year over the past 5 years

Risk Analysis

Shareholders have been diluted in the past year

A8D has negative shareholders equity.

Does not have a meaningful market cap (€74M)

Does not have meaningful revenue (€1M)

A8D Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

AB Science S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for AB Science
Historical stock prices
Current Share Price	€0.99
52 Week High	€1.69
52 Week Low	€0.93
Beta	1.18
1 Month Change	-18.51%
3 Month Change	-22.61%
1 Year Change	-32.93%
3 Year Change	-76.77%
5 Year Change	-93.53%
Change since IPO	-92.11%

Recent updates

Shareholder Returns

	A8D	DE Pharmaceuticals	DE Market
7D	3.6%	3.2%	-1.3%
1Y	-32.9%	22.2%	-2.0%

Return vs Industry: A8D underperformed the German Pharmaceuticals industry which returned 22.2% over the past year.

Return vs Market: A8D underperformed the German Market which returned -2% over the past year.

Price Volatility

Is A8D's price volatile compared to industry and market?
A8D volatility
A8D Average Weekly Movement	6.6%
Pharmaceuticals Industry Average Movement	5.3%
Market Average Movement	6.1%
10% most volatile stocks in DE Market	13.3%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: A8D has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: A8D's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2001	36	Alain Moussy	www.ab-science.com

AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company’s lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer’s disease, and indolent systemic mastocytosis, as well as in Phase 2 trial for mast cell activation syndrome and sickle cell disease. It also develops AB8939, a microtubule destabilizer in Phase 1 trial for the treatment of acute myeloid leukemia; and AB12319 in preclinical trial to treat sarcoma and solid tumors.

AB Science S.A. Fundamentals Summary

How do AB Science's earnings and revenue compare to its market cap?
A8D fundamental statistics
Market cap	€74.32m
Earnings (TTM)	-€1.56m
Revenue (TTM)	€1.17m

63.3x

P/S Ratio

-47.7x

P/E Ratio

Is A8D overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A8D income statement (TTM)
Revenue	€1.17m
Cost of Revenue	€196.00k
Gross Profit	€978.00k
Other Expenses	€2.54m
Earnings	-€1.56m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.02
Gross Margin	83.30%
Net Profit Margin	-132.62%
Debt/Equity Ratio	-66.6%

How did A8D perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/18 22:47
End of Day Share Price	2026/05/18 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AB Science S.A. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Michael Ryskin	BofA Global Research
Sébastien Malafosse	ODDO BHF Corporate & Markets
Justin Steven Smith	Societe Generale Cross Asset Research

AB Science (A8D) Stock Overview

Rewards

Risk Analysis

AB Science S.A. Competitors

Cantourage Group

MPH Health Care

Biofrontera

PEPTONIC medical

Price History & Performance

Recent News & Updates

AB Science Announces New Publication Demonstrating Substantial Survival Benefits and Preserved Quality of Life with Masitinib in Amyotrophic Lateral Sclerosis Patients

AB Science Provides Update on Clinical Development Program

AB Science SA Announces the Identification of A Plasma Biomarker That Indifies the Activity of Masitinib in Amyotrophic Lateral Sclerosis

AB Science Sa Reports Fourth Consecutive Case of Response from Phase 1 Data for the Combination of Ab8939 with Venetoclax for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia

AB Science S.A. has completed a Follow-on Equity Offering in the amount of €2.800001 million.

AB Science S.A. announced that it expects to receive €2.550001 million in funding

Recent updates

AB Science Announces New Publication Demonstrating Substantial Survival Benefits and Preserved Quality of Life with Masitinib in Amyotrophic Lateral Sclerosis Patients

AB Science Provides Update on Clinical Development Program

AB Science SA Announces the Identification of A Plasma Biomarker That Indifies the Activity of Masitinib in Amyotrophic Lateral Sclerosis

AB Science Sa Reports Fourth Consecutive Case of Response from Phase 1 Data for the Combination of Ab8939 with Venetoclax for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia

AB Science S.A. has completed a Follow-on Equity Offering in the amount of €2.800001 million.

AB Science S.A. announced that it expects to receive €2.550001 million in funding

AB Science SA Receives Regulatory Approval from European Countries to Initiate Third Stage of Phase I/II Study Combining Its Molecule AB8939 with Venetoclax for the Treatment of AML

AB Science Receives Approval from Several European Countries to Initiate the Confirmatory Phase 3 Study of Masitinib in ALS

AB Science S.A. has completed a Follow-on Equity Offering in the amount of €1.925003 million.

AB Science SA Receives FDA and EMA Authorization for Confirmatory Phase 3 Trial in Metastatic Castrate-Resistant Prostate Cancer

AB Science SA Announces New Peer-Reviewed Data Provide Strong Evidence Supporting Masitinib Potential for the Treatment of Alzheimer's Disease

AB Science SA Announces EMA Approval of Masivet Shelf-Life Extension to 4 Years

AB Science S.A., Annual General Meeting, Jun 30, 2025

AB Science Receives Chinese Patent Protecting Masitinib in the Treatment of Covid-19 Until 2041, Adding One More Indication with Long Term Intellectual Property Protection

AB Science SA Reports New Publication in the Scientific Journal PLOS One

AB Science S.A. Announces Positive Results from the Phase 2 Study of Masitinib in Covid-19

AB Science S.A. to Present New Data from Masitinib Clinical Program in Als in Two Presentations At the 2025 ENCALS Annual Meeting

AB Science SA Receives Notice of Allowance for Unites States Patent Covering Masitinib Until 2040 in the Treatment of Sickle Cell Disease

AB Science S.A. to Report First Half, 2025 Results on Sep 30, 2025

AB Science Provides an Update on Its Ab8939 Program in Acute Myeloid Leukemia

AB Science Receives Notice of Allowance for European Patent Covering Masitinib Until 2040 in the Treatment of Sickle Cell Disease

First half 2024 earnings released: €0.09 loss per share (vs €0.22 loss in 1H 2023)

AB Science Announces Positive Results of Its Phase 2 Study Evaluating Masitinib in Covid-19

Insufficient new directors

New minor risk - Market cap size

AB Science S.A., Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released

New minor risk - Financial data availability

AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALS

AB Science S.A. to Report First Half, 2024 Results on Sep 30, 2024

AB Science Receives Notice of Allowance for European Patent Covering masitinib Until 2036 in the Treatment of mastocytosis

First half 2023 earnings released: €0.22 loss per share (vs €0.15 loss in 1H 2022)

New minor risk - Financial data availability

New minor risk - Financial data availability

New minor risk - Shareholder dilution

AB Science S.A. Receives Notice of Allowance for European Patent Covering Masitinib in the Treatment of Metastatic Castrate Refractory Prostate Cancer (mCRPC)

Full year 2022 earnings released: €0.29 loss per share (vs €0.30 loss in FY 2021)

AB Science S.A. to Report Fiscal Year 2022 Results on Apr 28, 2023

AB Science S.A. Receives Approval from the U.S. Food and Drug Administration (FDA) to Initiate the Confirmatory Phase 3 Study with Masitinib in the Treatment of Progressive Multiple Sclerosis

AB Science S.A. announced that it expects to receive €15 million in funding from European Investment Bank, Investment Arm

AB Science SA Receives Notice of Deficiency from Health Canada for Masitinib in Treatment of Amyotrophic Lateral Sclerosis

AB Science SA Receives U.S. Food and Drug Administration Authorization to Initiate Confirmatory Phase 3 Clinical Study with Masitinib in the Treatment of Alzheimer’s Disease

AB Science Sa Receives First Agencies Authorizations to Initiate Confirmatory Phase 3 Clinical Study with Masitinib in the Treatment of Alzheimer's Disease

First half 2022 earnings released: EPS: €0 (vs €0.099 loss in 1H 2021)

AB Science SA Announces Positive Recommendation of Data and Safety Monitoring Board to Continue Phase 2 Study Evaluating Antiviral Activity of Masitinib in Covid-19

AB Science Announces That It Has Filed an Application for Conditional Marketing Authorization to EMA for Masitinib in the Treatment of ALS

AB Science SA Announces Publication of Results from its Positive Study of Masitinib in Severe Asthma Uncontrolled by Oral Corticosteroids in the Peer-Reviewed Journal of Asthma and Allergy

AB Science Announces Changes in the Board of Directors

AB Science S.A. Announces Publication of Results from Its Positive Pivotal Phase 3 Trial of Masitinib in Progressive Forms of Multiple Sclerosis in the Peer-Reviewed Journal Neurology® Neuroimmunology & Neuroinflammation

AB Science SA Announces Health Canada Has Granted Authorization to File New Drug Submission for Masitinib in the Treatment of ALS Under the Notice of Compliance with Conditions (NOC/c) Policy

AB Science SA Grants Authorization to Initiate Confirmatory Phase III Trial of Masitinib in Progressive Forms of Multiple Sclerosis by the Swedish Medical Products Agency

AB Science SA Receives Authorization to Initiate Phase II Study in Patients with Severe Mast Cell Activation Syndrome by the French Health Authority (ANSM)

AB Science Announces That It Has Been Granted Authorization to Initiate Confirmatory Phase III Trial of Masitinib in Progressive Forms of Multiple Sclerosis by the French Health Authority (ANSM)

AB Science S.A. Announces Dosing of First Patient in Phase 2 Trial of Masitinib’s Antiviral Activity Against the SARS-CoV-2 (Covid-19) Virus

AB Science Receives FDA Authorization to Initiate Phase 1/Ii Trial of Ab8939 in the Treatment of Acute Myeloid Leukemia

First half 2021 earnings released: €0.099 loss per share (vs €0.23 loss in 1H 2020)

AB Science SA Receives Regulatory Authorization to Commence A Second Phase 2 Covid-19 Study

AB Science S.A. Receives Health Canada Approval Letter to Commence Phase I/II Trial of Ab8939 in the Treatment of Acute Myeloid Leukemia (AML)

AB Science S.A. Receives Authorization to Resume Patient Enrollment in the Phase 2 Masitinib Study of Covid-19

AB Science S.A. Receives New Authorizations to Resume Patient Enrollment in Its Phase 3 Studies of Masitinib

AB Science Announces Results from Masitinib Study Ab12003 in Prostate Cancer Have Been Presented At the 2021 American Urological Association

AB Science SA Announces That It Has Received Second Authorization to Resume Patient Enrollment, in the Phase 3 Study of Masitinib in Mastocytosis

AB Science Announces Receives the First Authorization to Resume Patient Enrollment in the Confirmatory Phase 3 Study of Masitinib (AB19001) in ALS